石药，1类减肥新药，获批临床！

药融CDMO之家12-22 16:23

12 月 10 日，石药集团发布公告称，其开发的重组全人源抗 ActRIIA/IIB 单抗 JMT206已获美国 FDA 批准可在美国开展临床试验，适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。截图来源：石药集团公告JMT206 可同时特异性结合激活素受体 IIA 型(ActRIIA)与 IIB 型(ActRIIB)，阻断激活素 A(ActivinA)、肌抑素(GDF8)以及生长...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593487244?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-22 16:23","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2593487244","market":"hk","top_or_hot":-1,"title":"石药，1类减肥新药，获批临床！","media":"药融CDMO之家","content":"<div>\n<p>12 月 10 日，石药集团发布公告称，其开发的重组全人源抗 ActRIIA/IIB 单抗 JMT206已获美国 FDA 批准可在美国开展临床试验，适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。截图来源：石药 集团公告JMT206 可同时特异性结合激活素受体 IIA 型(ActRIIA)与 IIB 型(ActRIIB)，阻断激活素 A(ActivinA)、肌抑素(GDF8)以及生长...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163716a6c09eb5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药，1类减肥新药，获批临床！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药，1类减肥新药，获批临床！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-22 16:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163716a6c09eb5&s=b><strong>药融CDMO之家</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12 月 10 日，石药集团发布公告称，其开发的重组全人源抗 ActRIIA/IIB 单抗 JMT206已获美国 FDA 批准可在美国开展临床试验，适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。截图来源：石药 集团公告JMT206 可同时特异性结合激活素受体 IIA 型(ActRIIA)与 IIB 型(ActRIIB)，阻断激活素 A(ActivinA)、肌抑素(GDF8)以及生长...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163716a6c09eb5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163716a6c09eb5&s=b","article_id":"2593487244","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163716a6c09eb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593487244","pubTimestamp":1766391799,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025 年 11 月，JMT206 已率先获得 NMPA 批准临床试验，适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。2025年以来，截至12月初，石药集团共有15款1类新药首次获批临床，包括 8 款化药和7款生物制品。今年 4 月，该药也已获 FDA 批准开展临床试验。2 款肥胖新药首次获批 IND今年 3 月，石药集团百克生物递交的 SYH2067 胶囊获批临床，适应症为用于减少热量饮食和增加体力活动的基础上对成人超重或肥胖患者的体重管理。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK1191":"制药","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","BK1515":"抗疫概念","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","01093":"石药集团","BK1521":"挪威政府全球养老基金持仓","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD"},"translate_title":"CSPC, a new class 1 weight loss drug, has been approved for clinical use!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5},"content_text":"12 月 10 日，石药集团发布公告称，其开发的重组全人源抗 ActRIIA/IIB 单抗 JMT206已获美国 FDA 批准可在美国开展临床试验，适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。截图来源：石药 集团公告JMT206 可同时特异性结合激活素受体 IIA 型(ActRIIA)与 IIB 型(ActRIIB)，阻断激活素 A(ActivinA)、肌抑素(GDF8)以及生长分化因子 11(GDF11)与激活素受体 II 型(ActRII)的结合，从而抑制下游信号通路的激活，减少肌肉流失，并促进骨胳肌维持与增长，以达到增肌减脂的效果。同时，该产品亦可协助 GLP-1 受体激动剂实现更高质量的减重效果。临床前研究显示，JMT206 已表现出较高的生物利用度以及良好的有效性和安全性，具有较高的临床开发价值。2025 年 11 月，JMT206 已率先获得 NMPA 批准临床试验，适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。2025年以来，截至12月初，石药集团共有15款1类新药首次获批临床，包括 8 款化药和7款生物制品。从技术类型来看，这些产品中有3款siRNA疗法、3款ADC、1款单抗和1款双抗：来源：Insight 整理本文将挑选部分重要产品进行介绍，供参考。3 款 siRNA 疗法首次获批 INDSYH2061、SYH2070 和SYH2068 均为通过偶联乙酰半乳糖胺（GalNAc）实现肝脏靶向递送的 siRNA 药物。今年 10 月，SYH2061、SYH2070首次在国内获批临床，这 2 款产品也已获 FDA 批准开展临床试验。SYH2068 于今年 4 月首次在国内获批临床。SYH2061靶向补体蛋白 C5，能有效降低 C5 水平，是国内自主研发并进入临床试验阶段的首款超长效降低 C5 水平的 siRNA 药物，用于治疗IgA 肾病及其他补体介导相关性疾病。SYH2070 靶向血管生成素样蛋白3（ANGPTL3），有望成为超长效降低 ANGPTL3 的siRNA药物，用于治疗高甘油三酯血症或混合型高脂血症，具备有效降低残余胆固醇水平升高风险的潜力。SYH2068 靶向脂蛋白 (a)[Lp(a)]，有望成为超长效降低 Lp(a) 的 siRNA 药物，具有预防动脉粥样硬化性心血管疾病（ASCVD）的潜力。3 款 ADC 首次获批 INDSYS6041 是一款靶向 FRα的单抗 ADC，今年 1 月在国内获批临床，适应症为晚期实体瘤。它可与肿瘤表面的特异性受体结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用。今年 4 月，该药也已获 FDA 批准开展临床试验。SYS6045 是一款靶向HER2的 ADC 产品，今年 1 月在国内获批临床，适应症为实体瘤。目前正在开展 I/II 期临床，计划入组 266 名受试者，已完成招募。SYS6040 是一款靶向 DLL3的 ADC 产品，今年 3 月在国内获批临床，适应症为目前无标准治疗方案或标准治疗方案治疗失败或不耐受的晚期实体瘤参与者，包括小细胞肺癌、其他神经内分泌肿瘤和其他恶性实体瘤。今年 6 月，该药也已在美国获批开展临床试验。2 款肥胖新药首次获批 IND今年 3 月，石药集团百克生物递交的 SYH2067 胶囊获批临床，适应症为用于减少热量饮食和增加体力活动的基础上对成人超重或肥胖患者的体重管理。目前该产品正在开展 I 期临床，计划入组 118 名受试者。今年 11 月，JMT206 首次在国内获批临床，适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。JMT206 可同时特异性结合激活素受体IIA型（ActRIIA）与IIB型（ActRIIB），阻断激活素A（ActivinA）、肌抑素（GDF8）以及生长分化因子11（GDF11）与激活素受体II型（ActRII）的结合，从而抑制下游信号通路的激活，减少肌肉流失，并促进骨胳肌维持与增长，以达到增肌减脂的效果。同时，该产品亦可协助GLP-1受体激动剂实现更高质量的减重疗效。内容来源：丁香园Insight数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593487244","isCrawlerRequest":true}